Leap Therapeutics Valuation
| LPTX Stock | USD 2.58 0.01 0.39% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Leap Therapeutics secures a last-minute Real Value of $6.45 per share. The latest price of the firm is $2.58. Our model forecasts the value of Leap Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.81, shares owned by insiders of 17.28 %, and Current Valuation of 36.41 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Leap Therapeutics' valuation include:
Price Book 2.0195 | Enterprise Value 36.4 M | Enterprise Value Ebitda 0.4706 | Price Sales 160.1041 | Enterprise Value Revenue 1.8965 |
Undervalued
Today
Please note that Leap Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Leap Therapeutics is based on 3 months time horizon. Increasing Leap Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Leap Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Leap Stock. However, Leap Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.58 | Real 6.45 | Target 18.1 | Hype 2.58 | Naive 2.02 |
The intrinsic value of Leap Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Leap Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Leap Therapeutics helps investors to forecast how Leap stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Leap Therapeutics more accurately as focusing exclusively on Leap Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Leap Therapeutics' intrinsic value based on its ongoing forecasts of Leap Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Leap Therapeutics' closest peers.
Leap Therapeutics Cash |
|
Leap Valuation Trend
Analysing the historical paterns of Leap Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Leap Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Leap Therapeutics Total Value Analysis
Leap Therapeutics is now anticipated to have valuation of 36.41 M with market capitalization of 98.86 M, debt of 262 K, and cash on hands of 90.88 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Leap Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
36.41 M | 98.86 M | 262 K | 90.88 M |
Leap Therapeutics Asset Utilization
One of the ways to look at asset utilization of Leap is to check how much profit was generated for every dollar of assets it reports. Leap Therapeutics secures a negative usage of assets of -0.46 %, losing $0.004562 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Leap Therapeutics shows how discouraging it operates for each dollar spent on its assets.Leap Therapeutics Ownership Allocation
Leap Therapeutics maintains a total of 38.32 Million outstanding shares. 30% of Leap Therapeutics outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Leap Therapeutics Profitability Analysis
Net Loss for the year was (81.41 M) with profit before overhead, payroll, taxes, and interest of 1.5 M.About Leap Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Leap Therapeutics. We calculate exposure to Leap Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Leap Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -427 K | -405.6 K | |
| Pretax Profit Margin | (31.14) | (32.69) | |
| Operating Profit Margin | (31.76) | (33.35) | |
| Net Loss | (31.12) | (32.67) |
Leap Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 20.4 M |
Leap Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Leap Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Leap we look at many different elements of the entity such as Leap's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Leap Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Leap Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Leap Therapeutics' worth.Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.